The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10820 malaria professionals are enjoying the free benefits of MalariaWorld today

dihydroisoquinolone

Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones

February 23, 2021 - 14:17 -- Open Access
Author(s): 
Yizhe Chen, Fangyi Zhu, R. Kiplin Guy, et al.
Reference: 
Malaria Journal 2021 20:107, 19 February 2021

The ongoing global malaria eradication campaign requires development of potent, safe, and cost-effective drugs lacking cross-resistance with existing chemotherapies. One critical step in drug development is selecting a suitable clinical candidate from late leads. The process used to select the clinical candidate SJ733 from two potent dihydroisoquinolone (DHIQ) late leads, SJ733 and SJ311, based on their physicochemical, pharmacokinetic (PK), and toxicity profiles is described.

Subscribe to RSS - dihydroisoquinolone